{"DataElement":{"publicId":"10420448","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Administered Hour Minute Time","preferredDefinition":"A value that represents a period of time measured by hours and minutes when the filgrastim or bioequivalence agent was administered.","longName":"7810081v1.00:2635754v1.20","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7810081","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Administered","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act of having given something (e.g., a medication or test).","longName":"7810079v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7810079","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C1474:C37998:C71763:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0117CDB-A5DF-5E9A-E053-4EBD850ABA81","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0117CDB-A5ED-5E9A-E053-4EBD850ABA81","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2635754","version":"1.2","preferredName":"Hour Minute Time","preferredDefinition":"The continuum of experience in which events pass measured in hours and minutes. [Manually-curated]","longName":"2635754v1.2","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"TIME","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"format":"TIME (HR(24):MN)","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2635753","version":"1","preferredName":"Hour Minute Time","preferredDefinition":"In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.:A unit measure of time equal to 60 seconds.:the continuum of experience in which events pass from the future through the present to the past.","longName":"C25529:C48154:C25207","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hour","conceptCode":"C25529","definition":"A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Minute","conceptCode":"C48154","definition":"A unit measure of time equal to 60 seconds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD60EC2-D480-4C28-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-06","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2007-05-06","modifiedBy":"ONEDATA","dateModified":"2007-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"924CB33E-9F11-7B9B-E053-F662850AEA1E","latestVersionIndicator":"Yes","beginDate":"2019-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-09-12","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What time was filgrastim or biequivalence agent administered?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Alternate Question Text","description":"Time filgrastim or similar was administered:","url":null,"context":"NHLBI"},{"name":"NMDP Text 2","type":"Application Standard Question Text","description":"Time filgrastim or similar was administered:","url":null,"context":"NHLBI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3532-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-03","modifiedBy":"KUMMEROA","dateModified":"2023-06-14","changeDescription":null,"administrativeNotes":"2022.6.21 Released per KM. AK","unresolvedIssues":null,"deletedIndicator":"No"}}